ClinicalTrials.gg
CompletedNCT00144872Updated Sep 29, 2017

LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures

A Phase 1 interventional study of Lamotrigine in Seizure, Absence, sponsored by GlaxoSmithKline. Completed at 23 sites in United States. Open to participants aged Up to 12 Years. Per ClinicalTrials.gov, last updated 2017-09-29.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
Up to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Seizures by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Seizures · GlaxoSmithKline.

Enrollment
11th of 14
54 · median 179
Started
2004
with 2 others
Phase 1
Only one
of the 15
Registered
6th of 15
by date

Among the 15 studies in Seizures by GlaxoSmithKline, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2004, is the only one in phase 1, and was the 6th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 15 studies in Seizures by GlaxoSmithKline is open now. The open studies under Seizures, anywhere →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: Up to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Seizures by GlaxoSmithKline as a file.
02

Study summary

This is an open-label study evaluating the efficacy and safety of lamotrigine (LTG) for the treatment of newly-diagnosed typical absence seizures. Subjects will be children and adolescents \< 13 years of age. It will be conducted at multiple sites in the US. The study will consist of 4 phases: Screen Phase (up to 1 week), Baseline Phase (24 hours), Escalation Phase (up to 20 weeks) and Maintenance Phase (12 weeks). Subjects will receive increasing doses of LTG according to the dosing schedule until attaining seizure freedom as confirmed by hyperventilation (HV) for clinical signs and a 1-hr EEG at 2 consecutive weekly visits. At that point, subjects will move into the 12-week Maintenance Phase. Subjects who do not achieve seizure freedom upon reaching the maximum dose (10.2mg/kg/day) with the specified dose escalation will be discontinued from the study. During the Maintenance Phase, the investigators will use their best effort to maintain the subjects at the efficacious dose reached. If the subjects have unacceptable side effects or inadequate seizure control, the doses of study drug can be increased or decreased as specified in the dosing schedule. Safety will be assessed by monitoring adverse events, laboratory assessments, and serum lamotrigine levels. Health outcomes assessments will also be conducted.

03

Conditions studied

  • Seizure, Absence

Keywords

  • Absence Seizures
  • EEG
  • LTG
  • Typical Absence Epilepsy
  • Epilepsy
  • LAMICTAL
04

Who can participate

Ages eligible
Up to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly-diagnosed with absence epilepsy and never been treated with Anti-epileptic drugs (AEDs).
  • Diagnosis demonstrated on one of two 5-minute hyperventilation tests.
  • Investigator must judge that the subject and parent/guardian are likely to comply with all study procedures.
  • Parent/guardian must given written . Subjects who are intellectually able to understand the concepts and procedures of the protocol must give assent by also signing the consent or by signing a separate assent form.
  • Results of all screen assessments are judged to be clinically acceptable to the investigator and do not indicate any reasons why entry into the study would be .

Exclusion criteria

Exclusion criteria:

  • Seizures are the result of a currently active, known, and identifiable intracerebral lesion.
  • Has partial or generalized tonic-clonic seizures.
  • Has a progressive neurological disorder defined as being unstable for at least 12 weeks prior to the Screen Phase.
  • Has a psychiatric disorder requiring medication, or has had a past psychiatric condition that was both judged to be severe and required hospitalization.
  • Has any chronic cardiac, renal, or hepatic medical condition.
  • Has a condition that affects the absorption, distribution, metabolism, or excretion of drugs.
  • Is currently taking any psychoactive drugs to treat hyperactivity disorder or attention deficit disorder.
  • Has taken any drug within 12 weeks prior to the Screen Phase.
  • Is sexually active.
  • Is either pregnant (i.e., confirmed by pregnancy test at Screen) or breastfeeding.
  • Has a clinically significant chronic medical disorder which the investigator and/or GSK medical monitor determine warrants exclusion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Subjects receiving lamotrigine

    Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.

    Drug: Lamotrigine

Interventions

  • Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with no typical absence seizures for two consecutive weeks as confirmed by hyperventilation (HV) for clinical signs and 1-hour electroencephalogram (EEG)

    Time frame: Up to 8 months

Secondary outcomes

  1. Freq of seizures pre/post-treatment with lamotrigine, proportion of subjects with >=25, 50 and 75% decrease in seizure frequency, proportion of subjects with >=25, 50 and 75% decrease in clinical signs.

    Time frame: Up to 8 months

07

Study locations

23 sites
  • GSK Investigational Site
    San Jose, California 95128, United States
  • GSK Investigational Site
    Loxahatchee Groves, Florida 33470, United States
  • GSK Investigational Site
    Melbourne, Florida 32901, United States
  • GSK Investigational Site
    Panama City, Florida 32405, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Tampa, Florida 33607-6350, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Springfield, Missouri 65804, United States
  • GSK Investigational Site
    Newark, New Jersey 07103, United States
  • GSK Investigational Site
    Buffalo, New York 14222, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7600, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Nashville, Tennessee 37212, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Seattle, Washington 98105, United States
  • GSK Investigational Site
    Madison, Wisconsin 53792, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53215, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Holmes GL, Frank LM, Sheth RD, Philbrook B, Wooten JD, Vuong A, Kerls S, Hammer AE, Messenheimer J. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res. 2008 Dec;82(2-3):124-32. doi: 10.1016/j.eplepsyres.2008.07.016. Epub 2008 Sep 7. PubMed 18778916 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2004 to primary completion in Apr 2006, 17 months.

Of 16 phase 1 interventional studies under Seizures, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 56. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 5, 2005
StartActual
Nov 1, 2004
Primary completionActual
Apr 22, 2006
CompletionActual
Apr 22, 2006
Last update
Sep 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00144872
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 5, 2005
Start date
Nov 1, 2004
Primary completion
Apr 22, 2006
Completion
Apr 22, 2006
Last update
Sep 29, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamotrigine

Start the discussion